HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rivastigmine in frontotemporal dementia: an open-label study.

AbstractOBJECTIVE:
This preliminary open-label study aims to investigate the effects of rivastigmine, an inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), in 20 patients diagnosed with frontotemporal dementia (FTD).
PATIENTS AND METHODS:
Study subjects were men and women 60-75 years of age diagnosed with probable FTD. The rivastigmine group received doses of 3-9 mg/day. The control group included matched patients receiving antipsychotics, benzodiazepines and selegiline (deprenyl). All patients completed a 12-month follow-up period.
RESULTS:
Rivastigmine treatment was well tolerated. At 12 months, there was a general amelioration of behavioural changes as demonstrated by reductions in Neuropsychiatric Inventory (p<0.001 vs baseline and control), Behavioral Pathology in Alzheimer's Disease Rating Scale (p<0.001 vs baseline and control) and Cornell Scale for Depression in Dementia scores (p<0.05 vs baseline, p<0.001 vs control) in the rivastigmine group. Caregiver burden was reduced, as shown by reduced Relative Stress Scale scores (p<0.001 vs baseline and control). Mean scores on outcome measures evaluating executive function stabilised in the rivastigmine group (p<0.05 vs controls). Rivastigmine did not prevent the disease-related deterioration of cognition as assessed using the Mini-Mental State Examination.
CONCLUSION:
In this open-label study, rivastigmine-treated patients were less behaviourally impaired, and caregiver burden was reduced, at 12 months, compared with baseline. The use of cholinesterase inhibitors in FTD warrants further research.
AuthorsRita Moretti, Paola Torre, Rodolfo M Antonello, Tatiana Cattaruzza, Giuseppe Cazzato, Antonio Bava
JournalDrugs & aging (Drugs Aging) Vol. 21 Issue 14 Pg. 931-7 ( 2004) ISSN: 1170-229X [Print] New Zealand
PMID15554751 (Publication Type: Clinical Trial, Comparative Study, Journal Article)
Chemical References
  • Phenylcarbamates
  • Rivastigmine
Topics
  • Aged
  • Caregivers (statistics & numerical data)
  • Dementia (drug therapy, psychology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests (statistics & numerical data)
  • Phenylcarbamates (therapeutic use)
  • Rivastigmine
  • Statistics, Nonparametric
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: